Corporate Profile

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective inhibitor of the menin–KMT2A binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Through its pipeline agents, the Company is determined to realize a future in which people with cancer live longer and better than ever before. Syndax corporate headquarters are in Waltham, MA.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent Events

Syndax Fourth Quarter 2023 Conference Call

02.27.24 / 4:30 PM EST

Citi 2024 Virtual Oncology Leadership Summit

02.21.24 / 2:00 PM EST

Guggenheim 6th Annual Biotechnology Conference

02.08.24 / 10:00 AM EST

Sign Up for Email Alerts

Sign-up to automatically receive Syndax financial information by email.
Two people holding hands